Statera Biopharma (STAB) Short Interest Ratio & Short Volume $0.0001 0.00 (0.00%) As of 12:15 PM Eastern Add Compare Share Share Short Interest Stock AnalysisChartCompetitorsSEC FilingsShort InterestTrendsBuy This Stock Statera Biopharma Short Interest DataStatera Biopharma (STAB) has a short interest of 79,500 shares. This marks a 0.00% change in short interest from the previous month. The short interest ratio (days to cover) is 19.9, indicating that it would take 19.9 days of the average trading volume of 7,848 shares to cover all short positions.Current Short Interest79,500 sharesPrevious Short Interest79,500 sharesChange Vs. Previous MonthNo ChangeDollar Volume Sold Short$7.95Short Interest Ratio19.9 Days to CoverLast Record DateJuly 15, 2025Outstanding Shares53,300,000 sharesPercentage of Shares Shorted0.15%Today's Trading Volume1,939 sharesAverage Trading Volume7,848 sharesToday's Volume Vs. Average25% Short Selling Statera Biopharma? Sign up to receive the latest short interest report for Statera Biopharma and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartSTAB Short Interest Over TimeSTAB Days to Cover Over TimeSTAB Percentage of Float Shorted Over Time Statera Biopharma Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 7/15/202579,500 shares $7.95 No ChangeN/A19.9 $0.00 6/30/202579,500 shares $7.95 No Change0.1%18.5 $0.00 6/15/202579,500 shares $0.00 No Change0.1%18.9 $0.00 5/31/202579,500 shares $7.95 No Change0.1%22.7 $0.00 5/15/202579,500 shares $7.95 No ChangeN/A4.7 $0.00 4/30/202579,500 shares $7.95 No ChangeN/A12.6 $0.00 4/15/202579,500 shares $7.95 No ChangeN/A13.9 $0.00 3/14/202579,500 shares $7.95 No ChangeN/A3.8 $0.00 2/14/202579,500 shares $7.95 No ChangeN/A5 $0.00 1/31/202579,500 shares $7.95 No ChangeN/A8.5 $0.00 Get the Latest News and Ratings for STAB and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Statera Biopharma and its competitors with MarketBeat's FREE daily newsletter. 1/15/202579,500 shares $7.95 No ChangeN/A33.1 $0.00 12/30/2022774,500 shares $62.89 thousand -38.0%1.7%0.3 $0.08 12/15/20221,250,000 shares $135.88 thousand +50.8%2.8%0.3 $0.11 11/30/2022829,100 shares $103.64 thousand -37.7%1.8%0.2 $0.13 11/15/20221,330,000 shares $159.33 thousand -41.9%3.0%0.4 $0.12 10/31/20222,290,000 shares $320.60 thousand -4.2%5.2%0.8 $0.14 10/15/20222,390,000 shares $379.29 thousand +444.2%5.8%0.9 $0.16 9/30/2022439,200 shares $57.01 thousand -42.2%1.1%0.2 $0.13 9/15/2022759,200 shares $134.45 thousand -31.6%1.9%1.2 $0.18 8/31/20221,110,000 shares $200.47 thousand +5.7%2.7%1.5 $0.18 8/15/20221,050,000 shares $277.20 thousand -16.7%2.6%1.1 $0.26 7/31/20221,260,000 shares $264.35 thousand -9.4%3.1%1.1 $0.21 7/15/20221,390,000 shares $319.70 thousand -12.6%3.4%0.2 $0.23 6/30/20221,590,000 shares $453.15 thousand -23.6%3.9%0.2 $0.29 6/15/20222,080,000 shares $465.92 thousand +18.2%5.1%0.3 $0.22 5/31/20221,760,000 shares $407.62 thousand -4.9%4.3%0.2 $0.23 5/15/20221,850,000 shares $466.20 thousand -23.9%4.6%0.2 $0.25 4/30/20222,430,000 shares $812.84 thousand +275.2%6.0%0.3 $0.33 4/15/2022647,700 shares $198.71 thousand +320.6%1.6%0.2 $0.31 3/31/2022154,000 shares $48.51 thousand -28.3%0.4%0.1 $0.32 3/15/2022214,900 shares $130.34 thousand +218.4%0.8%0.2 $0.61 2/28/202267,500 shares $56.86 thousand -56.4%0.3%0.1 $0.84 2/15/2022154,800 shares $140.09 thousand +0.8%0.6%0.8 $0.91 1/31/2022153,600 shares $218.11 thousand -35.7%0.6%0.8 $1.42 1/15/2022238,700 shares $470.24 thousand +19.4%1.1%1.2 $1.97 12/31/2021199,900 shares $459.77 thousand No Change0.9%0.7 $2.30 STAB Short Interest - Frequently Asked Questions What is Statera Biopharma's current short interest? Short interest is the volume of Statera Biopharma shares that have been sold short but have not yet been closed out or covered. As of July 15th, traders have sold 79,500 shares of STAB short. Learn More on Statera Biopharma's current short interest. What is a good short interest ratio for Statera Biopharma? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. STAB shares currently have a short interest ratio of 20.0. Learn More on Statera Biopharma's short interest ratio. How does Statera Biopharma's short interest compare to its competitors? Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Statera Biopharma: Virpax Pharmaceuticals, Inc. (1.24%), Scopus BioPharma Inc. (0.02%), Evelo Biosciences, Inc. (0.04%), Comera Life Sciences Holdings, Inc. (0.01%), Genocea Biosciences, Inc. (0.33%), Aridis Pharmaceuticals, Inc. (0.04%), Ampio Pharmaceuticals, Inc. (0.01%), Clever Leaves Holdings Inc. (0.48%), eFFECTOR Therapeutics, Inc. (0.12%), OncoSec Medical Incorporated (0.00%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Coinbase Global, Inc. ($5.11 billion), Charter Communications, Inc. ($4.76 billion), Reddit Inc. ($2.84 billion), SoFi Technologies, Inc. ($2.79 billion), Seagate Technology Holdings PLC ($2.79 billion), Live Nation Entertainment, Inc. ($2.67 billion), Rocket Lab Corporation ($2.49 billion), AST SpaceMobile, Inc. ($2.12 billion), Moderna, Inc. ($2.09 billion), and Omnicom Group Inc. ($2.04 billion). View all of the most shorted stocks. What does it mean to sell short Statera Biopharma stock? Short selling STAB is an investing strategy that aims to generate trading profit from Statera Biopharma as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Statera Biopharma? A short squeeze for Statera Biopharma occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of STAB, which in turn drives the price of the stock up even further. How often is Statera Biopharma's short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including STAB, twice per month. The most recent reporting period available is July, 15 2025. More Short Interest Resources from MarketBeat Related Companies Virpax Pharmaceuticals Short Interest Data Scopus BioPharma Short Interest Data Evelo Biosciences Short Interest Data Comera Life Sciences Short Interest Data Genocea Biosciences Short Interest Data Aridis Pharmaceuticals Short Interest Data Ampio Pharmaceuticals Short Interest Data Clever Leaves Short Interest Data eFFECTOR Therapeutics Short Interest Data OncoSec Medical Short Interest Data Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:STAB) was last updated on 8/6/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored[Warning] Buffett Indicator hits new All-Time-HighWarren Buffett has leaned on one key indicator for decades—and it just hit an all-time high. That’s not bullis...Golden Portfolio | SponsoredInstant Cash (every 3rd Monday)Since 1973, Wall Street has quietly used a strange little pricing quirk to cash flow billions. Now, for the...Awesomely, LLC | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredAltucher: $900 to $108,000? Trump’s “Great Gain” Is HereJames Altucher says two recent events could trigger a historic wealth shift—one driven by a radical Trump poli...Paradigm Press | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Statera Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Statera Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.